Hetero Head On Remdesivir Partnering, Royalty Model
At Least Eight Bangladesh Firms Now In Fray
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.
